Bacterial Vaginosis (BV) - Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in BV therapeutics.
- More than 248 million total prevalent cases of BV are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for BV.
- Marketed drugs for BV are widely genericized and the majority of drugs indicated to treat BV are antibiotics.
- Out of 29 drugs in the pipeline for BV, only two are in the Phase III stage of development.
- Both commercial and academic sponsors lead the clinical trials space for BV over the past 10 years. TenNor Therapeutics has conducted the highest number of trials (six trials) among commercial sponsors.
- In deals involving companies developing BV assets, acquisitions were the most common deal type across Asia-Pacific, Europe, and North America.
GlobalData’s BV: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the BV market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BV market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Key Findings
- Disease Overview
- Disease Etiology
- Epidemiology Overview
- Epidemiology Overview: Total Prevalent Cases of BV in 2023 and 2028
- Treatment Overview
- Treatment Guidelines
- Treatment Algorithm
- Marketed Drugs Assessment
- Marketed Drugs – Leading Marketed Drugs in BV
- Marketed Drugs – Overview by Mechanism of Action
- Marketed Drugs – Overview by Route of Administration
- Marketed Drugs – Overview by Molecule Type
- Marketed Drug Profile – Merck's Primaxin/Tienam/Zienam
- Marketed Drug Profile – Lupin Pharma's Solosec
- Marketed Drug Profile – Starpharma's VivaGel BV
- Marketed Drug Profile – Organon's Xaciato
- Marketed Drug Profile – Mission Pharmacal's Tindamax
- Marketed Drug Profile – Bayer's Gynotran/Neo-Penotran
- Marketed Drug Profile – Sanofi's Flagyl/Metronide
- Marketed Drug Profile – NPO Petrovax Pharm's Polyoxidonium
- Pricing and Reimbursement Assessment
- Marketed Drugs – Annual Cost of Therapy
- Pipeline Drugs Assessment
- Pipeline Drugs Overview – Phase III and Phase II Pipeline Drugs in BV
- Pipeline Drugs – Overview by Development Stage
- Pipeline Drugs – Overview by Mechanism of Action
- Pipeline Drugs – Overview by Route of Administration
- Pipeline Drugs – Overview by Molecule Type
- Pipeline Drugs – Phase Transition Success Rate and Likelihood of Approval in BV
- Pipeline Drugs – Phase Transition Success Rate and Likelihood of Approval in Infectious Disease and BV
- Clinical Trials Assessment
- Clinical Trials in BV – Historical Overview
- Clinical Trials in BV – Overview by Phase
- Clinical Trials in BV – Overview by Status
- Clinical Trials in BV – Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in BV – Trials with a Virtual Component
- Clinical Trials in BV – Geographic Overview
- Clinical Trials in BV – Single-Country and Multinational Trials by Region
- Clinical Trials in BV – Top Sponsors with Breakdown by Phase
- Clinical Trials in BV – Top Sponsors with Breakdown by Status
- Clinical Trials in BV – Overview by Endpoint Status
- Clinical Trials in BV – Overview by Race and Ethnicity
- Clinical Trials in BV – Enrollment Data
- Clinical Trials in BV – Overview of Sites by Geography
- Clinical Trials in BV – Top 20 Countries for Trial Sites
- Clinical Trials in BV – Top 20 Sites Globally
- Clinical Trials – Feasibility Analysis: Geography Overview
- Clinical Trials – Feasibility Analysis: Benchmark Models for BV
- Deals Landscape
- Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in BV by Region
- Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in BV
- Commercial Assessment
- Commercial Assessment – Key Market Players in BV
- Future Market Catalysts
- Future Market Catalysts – Upcoming Market Catalysts in BV
- Appendix
- Methodology
- Methodology – Sales Forecasts
- Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook